Maj-Britt Jensen

15PUBLICATIONS
49CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsOncology and carcinogenesis not elsewhere classifiedHistorical, comparative and typological linguistics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 23, 2026
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1.

|May 23, 2025
Timely germline BRCA testing after invasive breast cancer promotes contralateral risk-reducing mastectomy and improves survival: an observational retrospective study.

Aleksandar M Kostov, Maj-Britt Jensen, Bent Ejlertsen

|Apr 22, 2025
Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo.

Signe Borgquist, Maj-Britt Jensen, Cecilie Linea Bendorff

|Mar 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.

Maj-Britt Jensen, Torsten O Nielsen, John Bartlett

|Jan 29, 2025
Germline BRCA testing in Denmark following invasive breast cancer: Progress since 2000.

Aleksandar M Kostov, Maj-Britt Jensen, Bent Ejlertsen

|Oct 23, 2024
Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.

Maj-Britt Jensen, Eva Balslev, Ann Søegaard Knoop

Pageof 3

Frequent Collaborators

11 joint publications

Bent Ejlertsen

4 joint publications

Deirdre P Cronin-Fenton

4 joint publications

Peer M Christiansen

3 joint publications

Anne-Vibeke Lænkholm